However, histologic transformation to SCLC remains one of the rare but aggressive resistance mechanisms to ALK inhibitors and poses as a challenge in clinical practice to improve patient outcomes.5, 6, 7, 8. The gene discussed is ALK; the disease is small cell lung carcinoma.